Schaible TF - Search Results

1

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Present DH, et al. Among authors: schaible tf. N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804. N Engl J Med. 1999. PMID: 10228190 Free article. Clinical Trial.

2

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. Targan SR, et al. Among authors: schaible tf. N Engl J Med. 1997 Oct 9;337(15):1029-35. doi: 10.1056/NEJM199710093371502. N Engl J Med. 1997. PMID: 9321530 Free article. Clinical Trial.

3

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Among authors: schaible tf. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.

4

Infliximab improves quality of life in patients with Crohn's disease.

Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Lichtenstein GR, et al. Inflamm Bowel Dis. 2002 Jul;8(4):237-43. doi: 10.1097/00054725-200207000-00001. Inflamm Bowel Dis. 2002. PMID: 12131606 Clinical Trial.

5

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. D'haens G, et al. Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3. Gastroenterology. 1999. PMID: 10220494 Clinical Trial.

6

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.

Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Cornillie F, et al. Aliment Pharmacol Ther. 2001 Apr;15(4):463-73. doi: 10.1046/j.1365-2036.2001.00956.x. Aliment Pharmacol Ther. 2001. PMID: 11284774 Free article. Clinical Trial.

7

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Baert FJ, et al. Among authors: schaible tf. Gastroenterology. 1999 Jan;116(1):22-8. doi: 10.1016/s0016-5085(99)70224-6. Gastroenterology. 1999. PMID: 9869598 Clinical Trial.

8

Randomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia.

Deprest JA, Nicolaides KH, Benachi A, Gratacos E, Ryan G, Persico N, Sago H, Johnson A, Wielgoś M, Berg C, Van Calster B, Russo FM; TOTAL Trial for Severe Hypoplasia Investigators. Deprest JA, et al. N Engl J Med. 2021 Jul 8;385(2):107-118. doi: 10.1056/NEJMoa2027030. Epub 2021 Jun 8. N Engl J Med. 2021. PMID: 34106556 Free PMC article. Clinical Trial.

9

Long term safety of infliximab.

Schaible TF. Schaible TF. Can J Gastroenterol. 2000 Sep;14 Suppl C:29C-32C. doi: 10.1155/2000/698523. Can J Gastroenterol. 2000. PMID: 11023558

10

[Treatment of inflammatory diseases: safety of long-term use of infliximab].

Schaible TF. Schaible TF. Presse Med. 2001 Mar 31;30(12):610-3. Presse Med. 2001. PMID: 11317923 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page